Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Andrew J. Armstrong, MD, MSc
Advertisement
Articles by Andrew J. Armstrong, MD, MSc
This management guide covers the treatment, diagnosis, and staging of prostate cancer.
Two experts discuss newly available and upcoming treatment options, such as abiraterone and MDV3100, for patients with castration-resistant prostate cancer.
These are, indeed, exciting times for patients with metastatic prostate cancer and the clinicians who care for them.
In 2010, we have the clinical opportunity to choose among several “targeted” agents when treating patients with metastatic renal cell carcinoma (RCC).
In this exclusive ASCO podcast, Andrew J. Armstrong, MD, ScM, Assistant Professor of Medicine and Surgery Duke Comprehensive Cancer Center, Departments of Medicine and Surgery, Divisions of Medical Oncology and Urology, addressed the vexing clinical issue of chemotherapy’s limited effectiveness in advanced renal cell carcinoma.
Advertisement
Latest Updated Articles
- What to Order From the Prostate Cancer Treatment Menu?
Published: January 17th 2012 | Updated:
Treatment of Castration-Resistant Prostate Cancer: Current Options and Novel TherapiesPublished: April 27th 2012 | Updated:
- New Generation of Targeted Therapies Show Promise in RCC
Published: June 7th 2010 | Updated:
- Prostate Cancer
Published: November 1st 2015 | Updated:
- ASCO 2010: Selected Sessions in Renal Cell Carcinoma
Published: July 2nd 2010 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Adjuvant Therapy Confers Postoperative ctDNA Clearance, DFS Benefit in CRC
2
Sacituzumab Tirumotecan Improves Survival in Second-Line EGFR+ NSCLC
3
Zanzalintinib Combo Improves Survival in Pretreated Metastatic CRC
4
Temab-A Displays Early Efficacy in Locally Advanced/Metastatic PDAC
5
